Section Arrow
URGN.NASDAQ
- UroGen Pharma Ltd
Quotes are at least 15-min delayed:2025/09/05 04:16 EDT
Pre Market
Last
 --
-- (--)
Bid
15.18
Ask
20
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 18.8
-0.57 (-2.94%)
Day High 
19.48 
Prev. Close
19.37 
1-M High
21.015 
Volume 
1.89M 
Bid
15.18
Ask
20
Day Low
18.17 
Open
19.35 
1-M Low
17.07 
Market Cap 
896.14M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 19.37 
20-SMA 19.28 
50-SMA 17.21 
52-W High 21.015 
52-W Low 3.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.01/0.11
Enterprise Value
1.02B
Balance Sheet
Book Value Per Share
-1.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
90.40M
Operating Revenue Per Share
1.57
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PPBTPurple Biotech Ltd0.78-0.64-45.07%0PE
Pre Market 0.7182 -0.0618 -7.92%
ADAPAdaptimmune Therapeutics plc0.051-0.0016-3.04%-- 
Pre Market 0.0477 -0.0033 -6.47%
NBYNovaBay Pharmaceuticals4.22+1.54+57.46%1.14PE
Pre Market 4.44 +0.22 +5.21%
ETHZETHZilla Corporation2.42-0.1-3.97%-- 
Pre Market 2.45 +0.03 +1.24%
RXRXRecursion Pharmaceuticals4.52-0.11-2.38%-- 
Pre Market 4.59 +0.07 +1.55%
Quotes are at least 15-min delayed:2025/09/05 04:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablationin forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.